Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment. (February 2018)

• Record Type: Journal Article
• Authors: Torén, William; Ansari, Daniel; Andersson, Bodil; Spelt, Lidewij; Andersson, Roland
• Is Part Of: Future oncology. Volume 14:Number 4(2018)
• Page Start: 343
• Page End: 351
• Publication Date: 2018-02
• Subjects: biomarker -- colorectal liver metastases -- predictive -- prognosis -- thymidylate synthase; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0431
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To investigate the role of thymidylate synthase (TS) as a predictive biomarker in patients with resected colorectal liver metastases (CRLM).Materials & methods: PubMed, EMBASE and Cochrane Library were queried up to June 2017. Meta-analysis was performed using random-effects model. Risk of bias was assessed using funnel plots.Results: Six eligible studies were included, comprising a total of 542 patients. Meta-analysis demonstrated a trend to reduced overall survival in patients with resected CRLM with TS overexpression, with a hazard ratio of 1.13 (95% CI: 0.99–1.29; p = 0.08). In three studies where patients received systemic fluorouracil, the pooled hazard ratio was 2.25 (95% CI: 1.37–3.71; p = 0.001).Conclusion: TS appears to be a clinically relevant predictive biomarker in patients with resected CRLM receiving systemic 5-FU.